Objective:To study the effect of licartin combined with pirarubicin transcatheter arterial chemoembolization (TACE) on apoptosis and epithelial - mesenchymal transition in unresectable liver cancer tissue.Methods: Pat...Objective:To study the effect of licartin combined with pirarubicin transcatheter arterial chemoembolization (TACE) on apoptosis and epithelial - mesenchymal transition in unresectable liver cancer tissue.Methods: Patients with unresectable liver cancer who were treated in Navy General Hospital between May 2014 and October 2016 were selected and randomly divided into two groups, the licartin group received licartin combined with TACE therapy, and control group received TACE therapy alone. The expression of tumor suppressor genes, autophagy marker genes and epithelial-mesenchymal transition marker genes in liver cancer lesions were determined before and after treatment.Results: After operation, RNF180, EBLN2, ALKBH5, Merlin, Beclin-1, LC3-II, TRAF-6 and E-cadherin protein expression in liver cancer lesions of both groups of patients were significantly higher than those before operation while Shh, Gli1, Snail, Twist, N-cadherin and Vimentin protein expression were significantly lower than those before operation, and RNF180, EBLN2, ALKBH5, Merlin, Beclin-1, LC3-II, TRAF-6 and E-cadherin protein expression in liver cancer lesions of licartin group were significantly higher than those of control group while Shh, Gli1, Snail, Twist, N-cadherin and Vimentin protein expression were significantly lower than those of control group.Conclusions:Licartin combined with pirarubicin TACE for unresectable liver cancer can more effectively induce apoptosis and autophagy, and inhibit epithelial-mesenchymal transition.展开更多
目的评价利卡汀(^(131)I美妥昔单抗)联合肝动脉栓塞化疗(TACE)治疗中晚期肝癌的效果与安全性。方法计算机检索Medline、Cochrane、Embase、SCI、CNKI、万方数据库(截至2016年3月)。收集比较利卡汀联合TACE与单纯TACE的临床对照试验。采...目的评价利卡汀(^(131)I美妥昔单抗)联合肝动脉栓塞化疗(TACE)治疗中晚期肝癌的效果与安全性。方法计算机检索Medline、Cochrane、Embase、SCI、CNKI、万方数据库(截至2016年3月)。收集比较利卡汀联合TACE与单纯TACE的临床对照试验。采用Rev Man 5.2统计分析软件对所有收集数据进行统计分析。结果共纳入8篇文献,其中2篇随机对照试验,6篇非随机对照试验,共967例患者。分析结果显示,联合组的近期有效率(OR=3.07,95%CI[2.06,4.58])、半年生存率(OR=1.46,95%CI[1.25,1.70])、一年生存率(OR=1.91,95%CI[1.41,2.57])、两年生存率(OR=2.19,95%CI[1.20,3.99])、疾病进展时间(MD=2.13,95%CI[1.88,2.38])与对照组比较,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,恶心呕吐(OR=1.48,95%CI[1.09,2.01])、白细胞减少(OR=2.53,95%CI[1.84,3.47])、血小板减少(OR=2.12,95%CI[1.55,2.88])、ALT(OR=1.59,95%CI[1.11,2.30])及胆红素(OR=1.76,95%CI[1.28,2.44])比较,差异有统计学意义(P<0.05),而发热、腹痛、AST、白蛋白比较,差异无统计学意义(P>0.05)。结论利卡汀联合TACE对于中晚期肝癌患者而言是一种安全且更有效的治疗手段,但仍需密切观察,积极预防处理不良反应。展开更多
基金Natural Science Foundation of China(30670612)China International Medical Foundation(Z-2014-06-15322)Navy Logistics Department(HJHQ-20130987).
文摘Objective:To study the effect of licartin combined with pirarubicin transcatheter arterial chemoembolization (TACE) on apoptosis and epithelial - mesenchymal transition in unresectable liver cancer tissue.Methods: Patients with unresectable liver cancer who were treated in Navy General Hospital between May 2014 and October 2016 were selected and randomly divided into two groups, the licartin group received licartin combined with TACE therapy, and control group received TACE therapy alone. The expression of tumor suppressor genes, autophagy marker genes and epithelial-mesenchymal transition marker genes in liver cancer lesions were determined before and after treatment.Results: After operation, RNF180, EBLN2, ALKBH5, Merlin, Beclin-1, LC3-II, TRAF-6 and E-cadherin protein expression in liver cancer lesions of both groups of patients were significantly higher than those before operation while Shh, Gli1, Snail, Twist, N-cadherin and Vimentin protein expression were significantly lower than those before operation, and RNF180, EBLN2, ALKBH5, Merlin, Beclin-1, LC3-II, TRAF-6 and E-cadherin protein expression in liver cancer lesions of licartin group were significantly higher than those of control group while Shh, Gli1, Snail, Twist, N-cadherin and Vimentin protein expression were significantly lower than those of control group.Conclusions:Licartin combined with pirarubicin TACE for unresectable liver cancer can more effectively induce apoptosis and autophagy, and inhibit epithelial-mesenchymal transition.
文摘目的评价利卡汀(^(131)I美妥昔单抗)联合肝动脉栓塞化疗(TACE)治疗中晚期肝癌的效果与安全性。方法计算机检索Medline、Cochrane、Embase、SCI、CNKI、万方数据库(截至2016年3月)。收集比较利卡汀联合TACE与单纯TACE的临床对照试验。采用Rev Man 5.2统计分析软件对所有收集数据进行统计分析。结果共纳入8篇文献,其中2篇随机对照试验,6篇非随机对照试验,共967例患者。分析结果显示,联合组的近期有效率(OR=3.07,95%CI[2.06,4.58])、半年生存率(OR=1.46,95%CI[1.25,1.70])、一年生存率(OR=1.91,95%CI[1.41,2.57])、两年生存率(OR=2.19,95%CI[1.20,3.99])、疾病进展时间(MD=2.13,95%CI[1.88,2.38])与对照组比较,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,恶心呕吐(OR=1.48,95%CI[1.09,2.01])、白细胞减少(OR=2.53,95%CI[1.84,3.47])、血小板减少(OR=2.12,95%CI[1.55,2.88])、ALT(OR=1.59,95%CI[1.11,2.30])及胆红素(OR=1.76,95%CI[1.28,2.44])比较,差异有统计学意义(P<0.05),而发热、腹痛、AST、白蛋白比较,差异无统计学意义(P>0.05)。结论利卡汀联合TACE对于中晚期肝癌患者而言是一种安全且更有效的治疗手段,但仍需密切观察,积极预防处理不良反应。
